Travere Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -59.6% | -59.6% | -23.2% |
| FY2022 | -649.9% | -649.9% | -41.4% |
| FY2023 | -55.5% | -55.5% | -14.1% |
| FY2024 | -544.3% | -544.3% | -54.1% |
| FY2025 | -22.2% | -22.2% | -4.2% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -59.6% | -59.6% | -23.2% |
| FY2022 | -649.9% | -649.9% | -41.4% |
| FY2023 | -55.5% | -55.5% | -14.1% |
| FY2024 | -544.3% | -544.3% | -54.1% |
| FY2025 | -22.2% | -22.2% | -4.2% |